Aquilo Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Aquilo Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,573	Closed	-$29K	–	14
2022 Q3	$29K	Sell	3,573 -858,034	-100%	-$7.77M	0.01%	15
2022 Q2	$6.01M	Sell	861,607 -893,899	-51%	-$8.69M	2.05%	12
2022 Q1	$26.5M	Buy	1,755,506 +245,562	+16%	+$3.86M	3.9%	9
2021 Q4	$33.1M	Buy	1,509,944 +410,000	+37%	+$10M	3.76%	7
2021 Q3	$29.7M	Buy	1,099,944 +154,562	+16%	+$4.41M	5.39%	8
2021 Q2	$22.8M	Buy	945,382 +644,496	+214%	+$19.7M	5.92%	9
2021 Q1	$13.1M	Buy	300,886 +280,886	+1,404%	+$12.4M	2.36%	12
2020 Q4	$829K	Buy	+20,000	New	+$826K	0.17%	17

Other funds holding FDMT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Aquilo Capital Management's FDMT Position: Q4 2022 in Review

Aquilo Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q4 2022, closing a stake of 3,573 shares — an estimated $29K sold.

Aquilo Capital Management first reported a position in FDMT in Q4 2020 and held it in 8 quarters. The position peaked at $33.1M in Q4 2021. 96 funds tracked by Wall St. Rank hold FDMT as of Q4 2022.

Aquilo Capital Management reported no remaining 4D Molecular Therapeutics position as of Q4 2022 after selling out during the quarter.
Aquilo Capital Management sold 3,573 4D Molecular Therapeutics shares in Q4 2022, an estimated $29K.
Aquilo Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 8 quarters.
Aquilo Capital Management's 4D Molecular Therapeutics position peaked at $33.1M in Q4 2021.
96 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2022.

Based on Aquilo Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.